These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35732409)

  • 1. Long-term remission of primary refractory ALK-positive anaplastic large cell lymphoma after allogeneic hematopoietic stem cell transplantation.
    Miyazaki M; Ichikawa S; Onishi Y; Fukuhara N; Furukawa E; Onodera K; Yokoyama H; Ichinohasama R; Harigae H
    J Clin Exp Hematop; 2022 Sep; 62(3):164-168. PubMed ID: 35732409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Successful bridging therapy with alectinib prior to allogeneic stem cell transplantation for refractory ALK-positive anaplastic large cell lymphoma].
    Kono A; Tanaka K; Shimada T; Bando K; Takahata A; Koi S; Yamamoto M; Mori T; Toyota S
    Rinsho Ketsueki; 2024; 65(3):158-163. PubMed ID: 38569859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case report: The utilization of crizotinib and brentuximab vedotin as a bridge to autologous stem cell transplantation and followed by CD30-directed CAR-T cell therapy in relapsed/refractory ALK+ ALCL.
    Liu W; Wu J; Ming X; Zhang Q; Zhou D; Zheng R; Zhou M; Shang Z; Chen L; Zhu X; Xiao Y
    Front Immunol; 2024; 15():1346001. PubMed ID: 38375471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Outcomes of 33 patients with anaplastic large cell lymphoma treated after hematopoietic stem cell transplantation].
    Lu N; Li XF; Dong YJ; Wang YN; Fu XR; Wu YM; Li YH; Wang MH; Li NN; Ren HY; Wang Z; Zhang MZ; Wu XX; Hu LD; Liu Y; Huang WR
    Zhonghua Xue Ye Xue Za Zhi; 2020 Feb; 41(2):117-122. PubMed ID: 32135627
    [No Abstract]   [Full Text] [Related]  

  • 5. Second allogeneic transplantation using umbilical cord blood for a patient with relapsed ALK+ anaplastic large cell lymphoma after allogeneic bone marrow transplantation in the era of ALK inhibitors: A case report.
    Saito S; Tashiro H; Sumiyoshi R; Matsuo T; Yamamoto T; Matsumoto K; Ooi J; Shirafuji N
    Medicine (Baltimore); 2021 Apr; 100(15):e25576. PubMed ID: 33847688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma.
    Ishizawa K; Yanai T
    Adv Ther; 2019 Oct; 36(10):2679-2696. PubMed ID: 31392578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anaplastic large cell lymphoma, ALK-negative.
    Ferreri AJ; Govi S; Pileri SA; Savage KJ
    Crit Rev Oncol Hematol; 2013 Feb; 85(2):206-15. PubMed ID: 22789917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful use of brentuximab vedotin for refractory anaplastic large cell lymphoma as a bridging therapy to haploidentical stem cell transplantation and maintenance therapy post-transplantation.
    Koh KN; Im HJ; Suh JK; Lee SW; Choi ES; Seo JJ
    Pediatr Blood Cancer; 2015 Jun; 62(6):1063-5. PubMed ID: 25641881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin.
    Oregel KZ; Everett E; Zhang X; Nagaraj G
    Expert Rev Anticancer Ther; 2016; 16(3):279-83. PubMed ID: 26809026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma.
    Foyil KV; Bartlett NL
    Cancer J; 2012; 18(5):450-6. PubMed ID: 23006951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Remission of relapsed/refractory classical Hodgkin lymphoma induced by brentuximab vedotin and pembrolizumab combination after allogeneic hematopoietic stem cell transplantation: a case report.
    Giannotti F; De Ramon Ortiz C; Simonetta F; Morin S; Bernardi C; Masouridi-Levrat S; Chalandon Y; Mamez AC
    Front Immunol; 2024; 15():1360275. PubMed ID: 38510239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, as a bridge to allogeneic stem cell transplantation in a patient with ALK-positive anaplastic large-cell lymphoma refractory to chemotherapy and brentuximab vedotin.
    Nakai R; Fukuhara S; Maeshima AM; Kim SW; Ito Y; Hatta S; Suzuki T; Yuda S; Makita S; Munakata W; Suzuki T; Maruyama D; Izutsu K
    Clin Case Rep; 2019 Dec; 7(12):2500-2504. PubMed ID: 31893088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leukaemic relapse of anaplastic large cell lymphoma, ALK negative.
    Karki NR; Badin K; Savage N; Bryan L
    BMJ Case Rep; 2021 Feb; 14(2):. PubMed ID: 33619137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategy for Pediatric Patients with Relapsed or Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma: A Review.
    Noguchi K; Ikawa Y
    Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease.
    Eyre TA; Khan D; Hall GW; Collins GP
    Eur J Haematol; 2014 Dec; 93(6):455-68. PubMed ID: 24766435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Successful allogeneic bone marrow transplantation with reduced intensity conditioning regimen for a pediatric relapsed ALK positive anaplastic large cell lymphoma].
    Hayase T; Niijima H; Tanaka D; Wada S; Kawahara Y; Oh Y; Morimoto A
    Rinsho Ketsueki; 2016 Jul; 57(7):859-63. PubMed ID: 27498729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Refractory Anaplastic Large Cell Lymphoma Rescued by the Combination of the Second-Generation ALK Inhibitor Brigatinib, High-dose Chemotherapy and Allogeneic Stem Cell Transplantation: A Case Report and Review of the Literature.
    Caddeo G; Tecchio C; Chinello M; Balter R; Zaccaron A; Vitale V; Pezzella V; Bonetti E; Pillon M; Carraro E; Mussolin L; Cesaro S
    Clin Hematol Int; 2023 Jun; 5(2-3):130-138. PubMed ID: 37072555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed/refractory CD30 positive lympho-proliferative disorders: a single centre experience.
    Mediwake H; Morris K; Curley C; Butler J; Kennedy G
    Intern Med J; 2017 May; 47(5):574-578. PubMed ID: 28247950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brentuximab vedotin for refractory anaplastic lymphoma kinase-negative anaplastic large cell lymphoma in leukemic phase with
    Yamashita Y; Hori Y; Kosako H; Oiwa T; Warigaya K; Mushino T; Murata S; Fujimoto M; Nishikawa A; Murata SI; Sonoki T; Tamura S
    Hematol Rep; 2020 May; 12(1):8368. PubMed ID: 32499905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Spontaneous remission of relapsed skin lesions of ALK-positive anaplastic large cell lymphoma after autologous stem cell transplantation].
    Yamazaki R; Koda Y; Abe R; Sakurai M; Kikuchi T; Kato J; Ouchi T; Mikami S; Mori T
    Rinsho Ketsueki; 2021; 62(1):25-29. PubMed ID: 33551421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.